I-Mab(US:IMAB) Jin Rong Jie·2025-08-11 13:48Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1] Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1] - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year improvement of 41.54% [1] Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1] Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on the development of innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [1] - The company's mission is to develop groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [1] - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [1]